\nConsiliul Concuren\u0163ei a amendat compania farmaceutic\u0103 Roche Rom\u00e2nia SRL cu 60 mil. lei (12,8 mil. euro) pentru abuz de pozi\u0163ie dominant\u0103 pe pia\u0163a unor produse oncologice, \u00een urma unor investiga\u0163ii \u00eencepute \u00een anul 2017.<\/p>\n
\n\u201e\u00cen cadrul primei investiga\u0163ii, autoritatea de concuren\u0163\u0103 a constatat c\u0103, \u00een perioada 2017 \u20132019, produc\u0103torul Roche a adoptat o strategie comercial\u0103 menit\u0103 s\u0103 elimine concuren\u0163a la licita\u0163ii \u015fi s\u0103 \u00eent\u00e2rzie intrarea pe pia\u0163\u0103 a unor medicamente similare. Comportamentul Roche s-a manifestat, \u00een cursul anului 2017, \u00een contextul particip\u0103rii la achizi\u0163ia public\u0103 centralizat\u0103 pentru medicamente ce con\u0163in substan\u0163ele Rituximab \u015fi Trastuzumab, \u00een cadrul programului na\u0163ional de oncologie, precum \u015fi \u00een cadrul a 47 de licita\u0163ii organizate la nivel de spital pentru aprovizionarea cu acelea\u015fi medicamente\u201d, se arat\u0103 \u00een comunicatul Concuren\u0163ei.<\/p>\n
\n\u00cen informarea autorit\u0103\u0163ii de concuren\u0163\u0103 se explic\u0103 faptul c\u0103 legisla\u0163ia prevede c\u0103 un produc\u0103tor trebuie s\u0103 furnizeze medicamente c\u0103tre minim trei distribuitori. Roche a v\u00e2ndut medicamentele care con\u0163ineau Rituximab \u015fi Trastuzumab cu un pre\u0163 mai mare dec\u00e2t cel oferit \u00een cadrul licita\u0163iilor publice.<\/p>\n
\n\u201eAceast\u0103 strategie pus\u0103 \u00een practic\u0103 cu ocazia particip\u0103rii la procedurile de achizi\u0163ie public\u0103, cu scopul de a \u00eent\u00e2rzia accesul pe pia\u0163\u0103 a produselor biosimilare, afecteaz\u0103 bugetul CNAS alocat programului na\u0163ional de oncologie. Economia realizat\u0103pe termen scurt de c\u0103tre Ministerul S\u0103n\u0103ta\u0163ii este aparent\u0103, pe termen lung, estim\u0103m c\u0103,\u00een cazul licita\u0163iei na\u0163ionale, alternativele biosimilare ar fi putut aduce economii de cca. 7,1 mil. euro bugetului programului na\u0163ional de oncologie\u201d, a spus Bogdan Chiri\u0163oiu, pre\u015fedintele Consiliului Concuren\u0163ei.<\/p>\n
\nProdusele Rituximab, Trastuzumab \u015fi Bevacizumab se folosesc \u00een cazul mai multor afec\u0163iuni oncologice, printre care leucemie limfocitar\u0103 cronic\u0103, cancer mamar, cancer ovarian, cancer renal.<\/p>\n
\nDe asemenea, Roche a direc\u0163ionat pacien\u0163ii c\u0103tre propriul produs Tarceva, mai scump, prin intermediul cardului de pacient \u015fi al call center \u2013ul Roche, ceea ce \u00eenseamn\u0103 c\u0103 bugetul CNAS a fost afectat cu 2 mil. lei, din calculele Consiliului Concuren\u0163ei.<\/p>\n
\nTarceva este un medicament care con\u0163ine substan\u0163a activ\u0103 Erlotinib \u015fi este utilizat \u00een tratamentul cancerului pulmonar, respectiv \u00een tratamentul cancerului pancreatic.<\/p>\n
\n\u00cen cadrul investiga\u0163iilor, Consiliul Concuren\u0163ei a efectuat inspec\u0163ii inopinate la sediul companiei.<\/p>\n","protected":false},"excerpt":{"rendered":"
Consiliul Concuren\u0163ei a amendat compania farmaceutic\u0103 Roche Rom\u00e2nia SRL cu 60 mil. lei (12,8 mil. euro) pentru abuz de pozi\u0163ie dominant\u0103 pe pia\u0163a unor produse oncologice, \u00een urma unor investiga\u0163ii \u00eencepute \u00een anul 2017.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[7343,8596,7553,44,323,8759],"class_list":["post-179346","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-amenzi","tag-consiliul-concurentei","tag-elvetia","tag-investigatii","tag-medicamente","tag-roche-romania"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/179346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=179346"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/179346\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=179346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=179346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=179346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}